BioPharma Resources

Drug Trial Radar · NCT01989754

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Dec 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 5,813 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,813

Actual

Start

Jan 16, 2014

Primary completion

Feb 23, 2017

Study completion Feb 23, 2017

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
The George Institute for Global Health, Australia
First posted
Nov 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and at elevated risk of cardiovascular events.

Conditions

  • Diabetes Mellitus, Type 2
  • Albuminuria

Interventions

  • PlaceboDrug

    One placebo capsule taken orally (by mouth) once daily for 156 weeks

  • Canagliflozin, 100 mgDrug

    One 100 mg capsule taken orally (by mouth) once daily

  • Canagliflozin, 300 mgDrug

    One 300 mg capsule taken orally (by mouth) once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression of AlbuminuriaTime frame: Up to 3 years

Locations

341 sites in 25 countries. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Carmichael, California

  • Site not named

    Concord, California

  • Site not named

    Pismo Beach, California

  • Site not named

    Roseville, California

  • Site not named

    Thousand Oaks, California

  • Site not named

    Denver, Colorado

  • Site not named

    Hollywood, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Opa-locka, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Palm Harbor, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Meridian, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Valparaiso, Indiana

  • Site not named

    Topeka, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Mandeville, Louisiana

  • Site not named

    Metairie, Louisiana

  • Site not named

    Elkridge, Maryland

  • Site not named

    Flint, Michigan

  • Site not named

    Picayune, Mississippi

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Washington, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Cornelius, North Carolina

  • Site not named

    Hickory, North Carolina

  • Site not named

    Mooresville, North Carolina

  • Site not named

    Canal Fulton, Ohio

  • Site not named

    Franklin, Ohio

  • Site not named

    Mason, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Beaver, Pennsylvania

  • Site not named

    Levittown, Pennsylvania

  • Site not named

    Norristown, Pennsylvania

Showing 40 of 341 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.